bs-13399R-BF405 [Conjugated Primary Antibody]
GSTK1/Glutathione S Transferase kappa 1 Antibody, AbBy Fluor® 405 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: GSTK1/Glutathione S Transferase kappa 1

Immunogen Range: 9-80/226


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 373156

Source: KLH conjugated synthetic peptide derived from human GSTK1/Glutathione S Transferase kappa 1

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

Members of the glutathione S-transferase (GST) family of proteins function in the detoxification of xenobiotics to protect cells against toxicant-induced damage. There are eight families of GST proteins, namely alpha, zeta, theta, kappa, mu, pi, sigma and omega, each of which are composed of proteins that have a variety of functions throughout the cell. GSTK1 (glutathione S-transferase kappa 1), also known as glutathione S-transferase subunit 13 (GST 13-13) or GSTK1-1, is a 226 amino acid ubiquitously expressed protein belonging to the kappa class of the GST superfamily that functions in cellular detoxification. Localizing to peroxisome, GSTK1 exists as a homodimer that catalyzes the conjugation of glutathione to a number of hydrophobic substrates leading to their removal from the cell.

Conjugation: AbBy Fluor® 405

Excitation/ Emission: 401nm/421nm

Size: 100ul

Concentration: 1ug/ul

Applications: IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 25


Predicted Cross Reactive Species: Human
Mouse
Rat
Dog
Cow
Sheep
Pig
Horse
Rabbit

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Arzu Kaya Kocdogan. et al. INVESTIGATION OF GST AND DRUG RESISTANCE PROTEIN EXPRESSIONS IN RELATION TO CHEMOTHERAPY IN BREAST CANCER. HEALTH PROBL CIVILIZ. 2024 May;18(1)Read more>>